VIP as a Potential Therapeutic Agent in Gram Negative Sepsis

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 12, Iss. 4, 2012-12 ,pp. : 308-315

Bentham Science Publishers

Access to resources Recommend Favorite

Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making: A Hypothetical Model of Biotechnology Therapy in Gram-Negative Sepsis

By Wang E.C.Y.  

PharmacoEconomics, Vol. 15, Iss. 4, 1999-04 ,pp. : 385-393

Adis International

Access to resources Recommend Favorite

Nitric oxide and calcium signaling regulate myocardial tumor necrosis factor-α expression and cardiac function in sepsis

By Zhang Ting   Feng Qingping  

Canadian Journal of Physiology and Pharmacology, Vol. 88, Iss. 2, 2010-02 ,pp. : 92-104

NRC Research Press

Access to resources Recommend Favorite

Differential Cytokine Response in Host Defence Mechanisms Triggered by Gram-negative and Gram-positive Bacteria, and the Roles of Gabexate Mesilate, a Synthetic Protease Inhibitor

By Iwadou H   Morimoto Y   Iwagaki H   Sinoura S   Chouda Y   Kodama M   Yoshioka T   Saito S   Yagi T   Tanaka N  

The Journal of International Medical Research, Vol. 30, Iss. 2, 2002-03 ,pp. : 99-108

Field House Publishing

Access to resources Recommend Favorite

Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor- synthesis

By Greten T.F.   Sinha B.   Haslberger C.   Eigler A.   Endres S.  

European Journal of Pharmacology, Vol. 299, Iss. 1, 1996-03 ,pp. : 229-233

Elsevier

Access to resources Recommend Favorite